Related Experiment Video

Updated: Mar 25, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.5K

Lipid Management in Human Immunodeficiency Virus

Merle Myerson1

  • 1Cardiovascular Disease Prevention Program & Lipid Clinic, Cardiology Section, Institute for Advanced Medicine (HIV), Mount Sinai St. Luke's, Mount Sinai Roosevelt, 1111 Amsterdam Avenue, New York, NY 10025, USA.

Endocrinology and Metabolism Clinics of North America
|February 20, 2016
PubMed

Insights

Antiretroviral therapy has transformed human immunodeficiency virus (HIV) from a fatal illness to a manageable condition. This review discusses general guidelines for managing dyslipidemia in HIV patients, highlighting knowledge gaps.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Pharmacology

Background:

  • Antiretroviral medications have significantly improved outcomes for patients with human immunodeficiency virus (HIV).
  • HIV infection and its treatment can impact lipid metabolism, leading to dyslipidemia.
  • Dyslipidemia poses cardiovascular risks, particularly relevant for the aging HIV-positive population.

Purpose of the Study:

  • To review current recommendations for the general population regarding dyslipidemia.
  • To suggest how these guidelines can be adapted for patients living with HIV.
  • To identify gaps in knowledge concerning the diagnosis and management of dyslipidemia in HIV-infected individuals.

Main Methods:

  • Review of existing clinical guidelines and relevant literature on dyslipidemia management.
  • Analysis of the applicability of general population guidelines to the specific context of HIV.
  • Identification of areas lacking sufficient research or evidence for HIV-positive patients.

Main Results:

  • General dyslipidemia guidelines offer a framework for managing lipid abnormalities in HIV patients.
  • Specific considerations for HIV treatment regimens and their impact on lipids are noted.
  • Significant gaps exist in understanding optimal diagnostic and management strategies for dyslipidemia in this population.

Conclusions:

  • While general guidelines provide a starting point, tailored approaches are needed for HIV patients.
  • Further research is crucial to address the specific challenges in diagnosing and managing dyslipidemia in individuals with HIV.
  • Closing these knowledge gaps will improve cardiovascular risk management in the HIV-positive community.

Keywords:
Antiretroviral therapyCardiovascular risk factorsDyslipidemiaHIVInfectious diseases

More Related Videos

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.8K
Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

3.0K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
1.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.8K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
16